Affiliation:
1. Department of Chemistry, Conju-probe, San Diego, CA 92121, California, USA
2. Department of Chemistry,
Bharath University, Chennai, Tamil Nadu, 600126, India
Abstract
Abstract:
Atopic dermatitis is epidermal hyperplasia, skin barrier dysfunction, and the
aberrant activation of immune cells. Janus kinase (JAK) is a family of cytoplasmic nonreceptor
tyrosine kinases that consists of four members, such as JAK1, JAK2, JAK3, and
TYK2. The JAK signaling pathway plays a critical role in a wide range of autoimmune
and inflammatory diseases, including atopic dermatitis. Abrocitinib is an orally bioavailable
and selective JAK1 inhibitor, and it was approved in January, 2022, for the treatment
of atopic dermatitis. The chemical structure and physical properties of abrocitinib, its synthesis,
mechanism of action, and pharmacokinetic profile are summarized.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献